Japanese regulations and JSQA update. Tadahiro Yoshiyama International Affairs Committee Director of GLP Division November 11, 2016
|
|
- Marybeth Harvey
- 5 years ago
- Views:
Transcription
1 Japanese regulations and JSQA update Tadahiro Yoshiyama International Affairs Committee Director of GLP Division November 11, 2016
2 Contents Japanese regulatory updates of the GxP systems Recent activities in JSQA Expectations of new collaborations between RQA and JSQA International Affairs Committee / JSQA 11/11/2016 2
3 Japanese regulatory updates of the GxP systems International Affairs Committee / JSQA 11/11/2016 3
4 Summary Over the past year, a partial revision and expansion of the evaluation scope occurred in the Japanese GxP systems The inspection methods and perspectives of the Japanese regulatory authority may be changed International Affairs Committee / JSQA 11/11/2016 4
5 Expansion of the GLP evaluation scope 1. Coming into effect in GLP ordinance for cellular and tissue based products Ministerial Ordinance on Good Laboratory Practice for Non Clinical Safety Studies of Cellular and Tissue Based Products (Ordinance of the Ministry of Health and Welfare No. 88 of July 30, 2014) 2. Start of the facility inspection by PMDA and inspection of 8 facilities has already been carried out JSQA started collection and analysis of the information about the inspection by PMDA in GLP subcommittee 5 International Affairs Committee / JSQA 11/11/2016
6 Coming into effect in New OECD Advisory Document on GLP computerized system OECD SERIES ON PRINCIPLES OF GOOD LABORATORY PRACTICE AND COMPLIANCE MONITORING Number 17 Impact in the CSV activity in Japan Responsibility of the Facility Management newly recognized Scope Validation activity of the appropriate frequency according to a risk assessment results Personnel Life Cycle Importance of the participation of Study director, IT person and system vendor Periodic Review Securing of quality of Electric Record& Signature System Inventory Validation strategy based on potential risks to data integrity Risk Assessment Up-to-date listing of all GLP-relevant systems International Affairs Committee / JSQA 6
7 Japanese Compassionate Use (J-CU) has begun at last Japanese Good Clinical Practice (J-GCP) was partially revised this year, because the inclusion of J-CU. the partial revision of J-GCP for Drugs MHLW Ministerial Ordinance No.9 became effective from Jan 22, the partial revision of J-GCP for Medical Devices MHLW Ministerial Ordinance No.128 became effective from Jul 21, the partial revision of J-GCP for Regenerative Medicines MHLW Ministerial Ordinance No.129 became effective from Jul 21, J-CU applications 3 protocols were published. (As of 30 Sep., 2016) International Affairs Committee / JSQA 11/11/2016 7
8 Revision of the recent GVP-related law Revision of the Pharmaceutical Affairs Law (November 27, 2013) GVP-related laws were revised(july 30, 2014) Summery of Revision GVP ordinance Cellular and tissue based products were increased as an object of post-marketing safety management operations Pharmaceutical Affairs Law Enforcement Regulation About the entrustment of post-marketing safety management operations, Re-entrustment was accepted, under the constant condition 8 International Affairs Committee / JSQA 11/11/2016
9 Recent GVP In-compliances In one company, advance reaction was not reported within the period by system failure. Medicinal Product : 5475 cases (57 ingredients) Investigational Products: 154 cases (28 ingredients) Correspondence of the MHLW To One company which violated Business Suspension Order :15 days Business Improvement Order : Twice To Representatives of first-class Pharmaceutical marketing authorization holders (271 Companies) Requested to do Voluntary Self-Inspection about the inhouse GVP systems Result In 20 companies, the defects of the procedure were found out In 6 companies, Advance reaction information unreported (88 cases in total 133 examples)
10 Recent activities in JSQA Making of medium and long term administration policies, covering the next 5 years International Affairs Committee / JSQA 11/11/
11 Making of medium and long term administration policies and schedules JSQA set the policies and plans for our activities in line with the change in environment Structure of Members (As of 31 Aug., 2016) 1366 members from 426 companies GQP/GVP/GPSP Division 15% GLP Division 37% GCP Division 48% GLP Division: 496 members from 155 companies GCP Division: 662 members from 187 companies GQP/GVP/GPSP Division: 208 members from 84 companies International Affairs Committee / JSQA 11/11/
12 Making of medium and long term administration policies and schedules Policies and schedules aim at getting the following results in five years Announcement of the outcome of the selected study Publication of the activity result by methods such as a presentation at the meeting or the article contribution. Collection of outside evaluations about activities and referring them to the next problem setting meeting. Completion of the educational training system & establishment of the QA authorization Establishment of the QA authorization in each GxP system. International Affairs Committee / JSQA 11/11/
13 Making of medium and long term administration policies and schedules Policies and schedules aim at getting the following results in five years The strengthening of the liaison between external/internal related associations and regulatory authorities Collaboration with external/internal related associates and regulatory authorities. Further cooperation between RQA, SQA and JSQA, about 5 th and 6 th GQAC. Arrangement of operations and systems, leading to activation Increase the number of members engaged in the GQP/GMP/ GDP, Medical device or QMS. International Affairs Committee / JSQA 11/11/
14 Expectations of new collaborations between RQA and JSQA International Affairs Committee / JSQA 11/11/
15 Effective use of collaborations JSQA is expecting further collaborations with RQA, on various topics The making of deliverables through collaborations The employment of RQA training materials for JSQA personnel The holding of periodical meetings about an discussion items International Affairs Committee / JSQA 11/11/
16 Autumn Scenes in Japan JSQA will support the 5th GQAC.So, through cooperation and information sharing, let's make this event a success. 11/11/20 International Affairs Committee / JSQA 16 16
17 Effective use of collaborations The deliverables which come from the material of the collaboration. Activity Summary of 12th Term( ) - GLP Division - GCP Division - GQP/GVP/GPSP Division - Common Special Project 1, 2 Activity Summary of 11th Term( ) - GLP Division - GCP Division - Common Special Project 1, /11/ International Affairs Committee / JSQA
18 Thank you ありがとうございました International Affairs Committee / JSQA 11/11/
CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS
CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS Post-marketing surveillance (PMS) to assure the quality, efficacy and safety of drugs after they go on the market and to establish proper methods of use of
More informationIndian Pharmacopoeia Commission
Indian Pharmacopoeia Commission JP 130 th Anniversary Symposium Tokyo, Japan 15 th Sept, 2016 Dr.G.N.Singh Secretary cum Scientific Director, Overview Indian Pharmaceutical Industry Pharmacopoeia and NFI
More informationOverview of Generic Drug Policy and Introduction of its Review Points/BE Guideline in Japan
1 5 th Joint Conference of Taiwan and Japan on Medical Products Regulation Overview of Generic Drug Policy and Introduction of its Review Points/BE Guideline in Japan Mr. Yoshihiko Sano Deputy Director,
More informationReports of Adverse Drug Reactions, etc. of Pharmaceuticals
(Attachment) Reports of Adverse Drug Reactions, etc. of Pharmaceuticals 1 GLOSSARY (1) Drugs, quasi-drugs, and cosmetics -1- Related to Article 228-20, paragraph 1, item 1 of the Enforcement Ordinance
More informationGLP Update and Hot Topics
GLP Update and Hot Topics RQA Annual Conference Mark Goodwin 9 Nov 2016 Introduction International GLP Updates OECD including MAD Agreement EC/ EMA US FDA & US EPA UK GLP Update MHRA MHRA GLP Deficiencies
More informationMs. Wajihah Binti Haji Zainuddin Halal Food Control Division, MoRA. Brunei Seminar & Showcase ASEAN-Japan Hall February 25, 2014
Ms. Wajihah Binti Haji Zainuddin Halal Food Control Division, MoRA Brunei Seminar & Showcase ASEAN-Japan Hall February 25, 2014 1 Presentation Overview Halal Certifying Body Procedure of Halal Certification
More informationAgenda. The current state of Pharmaceutical Excipients in Japan -JPE, JP, DMF, GAB (GMP Auditing Board)- Pharmaceutical Excipients
The current state of Pharmaceutical Excipients in Japan -JPE, JP, DMF, GAB (GMP Auditing Board)- Dr. Keiji Kijima, Secretary General, IPEC Japan April 26, 2012 Agenda JPE (Japanese ) JP (Japanese Pharmacopoeia)
More informationPoints to Consider CPhI Japan Briefing Session on Pharmaceutical Regulations in Japan
2013 CPhI Japan Briefing Session on Pharmaceutical Regulations in Japan The Master File System and Points to Consider Kentaro Hashimoto, Master File Management Group, Division of Pharmacopoeia and Standards
More informationRegulatory Systems of Health Claims in Japan. June, 2011 Consumer Affairs Agency Food Labelling Division
Regulatory Systems of Health Claims in Japan June, 2011 Consumer Affairs Agency Food Labelling Division Mission of the Consumer Affairs Agency (CAA) Article 2 of the Consumer Basic Act sets out the state
More informationOn Release of Questions and Answers (Q&As) regarding the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents
Administrative Notice 1 July 9, 2010 To: Pharmaceutical Affairs Divisions, Prefectural Public Health Bureaus (Departments) From: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau,
More informationWelcome to Celerion s Dinner and Discussion Program Tokyo, Japan Apr 2, 2015
Welcome to Celerion s Dinner and Discussion Program Tokyo, Japan Apr 2, 2015 Fast to Patient: The Push For Earlier Signals of Efficacy in Clinical Research J. Fred Pritchard, Ph.D. Vice President, Global
More informationYui Matsuda, PhD, RN, MPH, YunKyung Chang, PhD, RN, Todd Schwartz, DrPH & Linda S. Beeber, PhD, RN, CS, FAAN
Associations among maternal depressive symptoms, maternal diathesis factors and family characteristics in families with young children having developmental delay or disability Yui Matsuda, PhD, RN, MPH,
More informationTest Article Analyses in Compliance with Good Laboratory Practice in Japan: Circumstances and Changes
Test Article Analyses in Compliance with Good Laboratory Practice in Japan: Circumstances and Changes Harumi Namiki 1, *, Tetsuya Shigeta 2, Yoshitaka Ino 3, Kanzo Kimura 4, Katsutoshi Inaba 5, Sachio
More informationThe use of the CTQA model also holds promise for easier identification of opportunities for improvement by enabling the clarification of metrics and K
Study Group Study Group 1: QMS Subgroup C-1-A Construction of a Quality Assurance System for Clinical Trials Subgroup A, Study Group 1 (hereinafter, this group) worked on the following tasks based on the
More informationSingapore s Progress on GLP and MAD
2010/SOM1/CD/WKSP/025 Agenda Item: Afternoon Session I Singapore s Progress on GLP and MAD Submitted by: Singapore Case Study Workshop on the Chemicals Sector - From Principles to Practice Hiroshima, Japan
More information- Notification to specify uniform limit (Ministry of Health, Labour and Welfare Notification No. 497, 2005)
Syoku-An No.1129001 November 29, 2005 *1 Director Notice *2 Department of Food Safety Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare Establishment of Applicable Laws and Ordinances
More informationStandard Operating Procedure. Selection of studies performed in compliance with Good Laboratory Practice for audit purposes
Scope To describe the procedure for EFSA to request on a yearly or ad-hoc basis the performance of GLP studies audits by the GLP Monitoring Authorities. To lay down criteria for the selection of the GLP
More informationAQPWBRoyhbThSIjE: :42:34 : 1XCrl6 vjcbuwhpahpe, [url= Cartridges, device kits, power options.
corp@stantec.com Latest Press Release chrome has been freezing S Thought Of The Day. ADVERTISEMENT Get the latest news and analysis in the stock market today, including national and world stock market
More informationProgram to Promote Use of Generic Drugs in Japan
Program to Promote Use of Generic Drugs in Japan March 22, 2012 CPhI Japan 2012 Tsuyoshi Matsuno Economic Affairs Division, Health Policy Bureau, Ministry of Health, Labour and Welfare * A Japanese translation
More informationHow does economic deprivation lead to problem drinking?
The 6 th Doshisha - Chung-Ang University Joint Seminar on East Asian Social Welfare How does economic deprivation lead to problem drinking? : The mediating effect of income inequality consciousness and
More informationMHRA Pharmacovigilance System Master File (PSMF) Inspection Findings
MHRA Pharmacovigilance System Master File (PSMF) Inspection Findings Gretel Sakyi Medical Information and Patient Safety Manager AstraZeneca UK 07 June 2018 Agenda MHRA inspections How inspectors use the
More informationPMDA Perspectives on Oncology Panel. REIKO YANAGIHARA, Ph.D. Office of In Vitro Diagnostics PMDA
15th DIA Japan Annual Meeting 2018 Promoting Better Collaboration to Drive Global Health and Innovation in an Era of Medical and Scientific Transformation November 11-13, 2018 Tokyo Big Sight PMDA Perspectives
More information1 2 3 Based on the contents detailed below, assess the substantial equivalence to a legally marketed predicate device. In that case, the standards, et
Attachment 8 Application for Treatment Positive Airway Pressure Unit, etc. (1) Scope of application Continuous positive airway pressure units and Continuous-automated positive airway pressure units in
More informationNattha Kerdsakundee,Ph.D. Regional Manager Department of International Trials
Nattha Kerdsakundee,Ph.D. Regional Manager Department of International Trials Disclaimer These Power Point slides are the intellectual property of NCGM under the copyright laws. Used by permission. All
More informationHeng-Jung Lien 衛生福利部食品藥物管理署. Section Chief. Food and Drug Administration, Ministry of Health and Welfare
Heng-Jung Lien Section Chief Division of Medicinal Products, Food and Drug Administration, Ministry of Health and Welfare, Taiwan, R.O.C. 衛生福利部食品藥物管理署 Food and Drug Administration, Ministry of Health and
More informationSurgery of the spleen and liver an introduction Liver Fossum chapter 21. Liver diagnostics. Liver diagnostics
Surgery of the spleen and liver an introduction 2017 11 30 Liver Fossum chapter 21 For diagnostics Biopsy of the liver! Portosystemic shunts the principle The Gallbladder disease and treatment Always biopsy
More informationMHRA Pharmacovigilance Inspections: Prepare and Manage for Success
MHRA Pharmacovigilance Inspections: Prepare and Manage for Success Created and Presented by Miranda Dollen Vice President, Pharmacovigilance & EEA QPPV Mapi 2016, All Rights Reserved 2 Prepare and Manage
More informationDirector-General, Department of Food Safety, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare
Notice No. 0315 Article 1 of the Department of Food Safety March 15, 2012 To: All the Prefectural Governors All the Mayors in Cities with Public Health Centers All the Mayors of Special Wards Director-General,
More informationGLOBAL BIOANALYSIS CONSORTIUM
GLOBAL BIOANALYSIS CONSORTIUM Scope and Regulations Harmonization Team: A1 (Work in Progress) John Smeraglia on behalf of the HT-A1 A1: Scope and regulations Team members: Team lead Region Expertise Surendra
More informationWhy Do You Study? Complex Answers to a Simple Question. Mimi Bong. Department of Education Brain & Motivation Research Institute Korea University
Why Do You Study? Complex Answers to a Simple Question Mimi Bong Department of Education Brain & Motivation Research Institute Korea University 1 interest self-efficacy volition Self-defeating ego goals
More informationEVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON DISINTEGRATION TEST GENERAL CHAPTER Q4B ANNEX 5(R1)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationBasic guidelines for promotion of control measures for hepatitis
Basic guidelines for promotion of control measures for hepatitis May 16, 2011 Table of Contents Chapter 1 Basic approach for preventing hepatitis and promoting medical care of hepatitis - 2 - Chapter 2
More informationClinical trial consultation system (utility and successful cases from company s point of view)
Clinical trial consultation system (utility and successful cases from company s point of view) 3 rd China-Japan Symposium on Drug Development March 22, 2012 Japan Pharmaceutical Manufacturers Association
More informationSTAFF REPORT City of Lancaster NB 2
STAFF REPORT City of Lancaster NB 2 12/13/16 MVB Date: December 13, 2016 To: From: Subject: Mayor Parris and City Council Members Mark V. Bozigian, City Manager Allison E. Burns, City Attorney Ordinance
More informationAdaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient
Adaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient Michelle L. Combs, PhD Vice President, Clinical Pharmacology Sciences New Drug And Biologics
More information(Tentative Translation)
(Tentative Translation) Public Notice of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the Ministry of Health, Labour and Welfare (MHLW) No. 2 of December 17, 2010 Table
More information4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP
New Mexico s Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy New Mexico and the PMP In 2012, New Mexico had the 3 nd Highest Overdose Death Rate in Nation.! 492 Deaths or a rate of 23.6
More informationTERMS AND CONDITIONS NATIONAL GOOD LABORATORY PRACTICE (GLP) COMPLIANCE MONITORING AUTHORITY
TERMS AND CONDITIONS OF NATIONAL GOOD LABORATORY PRACTICE (GLP) COMPLIANCE MONITORING AUTHORITY FOR OBTAINING AND MAINTAINING ITS GLP CERTIFICATION BY A TEST FACILITY Document No.GLP-101 Version/Issue
More informationNational Strategies for Controlling Avian Influenza Viruses
National Strategies for Controlling Avian Influenza Viruses Viet Nam Background information Animal population Major animal diseases of concerns Population of Livestock in Viet Nam Year Buffalo Cattle Pigs
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationPreparing for Electronic Prescribing of Controlled Substances (EPCS) in New York
Preparing for Electronic Prescribing of Controlled Substances (EPCS) in New York Ken Whittemore, Jr. R.Ph., MBA Senior VP, Professional & Regulatory Affairs Copyright Copyright 2015 by 2015 Surescripts,
More informationMitigation of risk and selection of clinical starting dose a PMDA nonclinical perspective
Mitigation of risk and selection of clinical starting dose a PMDA nonclinical perspective Mineo Matsumoto DVM, PhD, DJST Office of New Drug Ⅱ Pharmaceutical and Medical Devices Agency Disclaimers The views
More informationQuality of Clinical Trials -PMDA s Point of View-
Quality of Clinical Trials -PMDA s Point of View- Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan The views presented in this presentation are those of the author
More informationGovernment structure on Food safety and Animal health system in Japan
Government structure on Food safety and Animal health system in Japan Japan-EU EPA Negotiation Round 4 SPS group meeting 28-29 January, 2014 Food Safety & Consumer Affairs Bureau Ministry of Agriculture,
More informationThe Second Draft of Provisional Maximum Residue Limits (MRLs) for Agricultural Chemicals in Foods
The Second Draft of Provisional Maximum Residue Limits (MRLs) for Agricultural Chemicals in Foods The Ministry of Health, Labour and Welfare revised Food Sanitation Law in May 2003. Based on the revised
More informationCommitted to Environment, Health, & Safety
Committed to Environment, Health, & Safety Environment, Health, and Safety Management System and Policy of W. R. Grace & Co. November 8, 2018 The Grace Environment, Health, and Safety Management System,
More informationEPA REGULATORY UPDATE
SOCIETY OF QUALITY ASSURANCE REGULATORY FORUM EPA REGULATORY UPDATE Linthicum Heights, Maryland January 24, 2008 Robert Cypher United States Environmental Protection Agency 2/13/2008 SQA Baltimore 1 ANY
More informationUpdate on JP-TW OTC drugs WG
Update on JP-TW OTC drugs WG Fumihito Takanashi Office of International Regulatory Affairs, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labor and Welfare (MHLW) 7, December,
More informationThe Danish Medicines Agency s availability strategy
låst DECEMBER 2016 The Danish Medicines Agency s availability strategy 2017 2021 Danish Medicines Agency, 2016 This publication may be freely quoted with appropriate acknowledgement of the source. Images
More informationEnsuring the gap between science and practice is filled safely - MHRA
Safeguarding public health Ensuring the gap between science and practice is filled safely - MHRA Diane Leakey Head of Information and Communications, MHRA April 2012 Agenda Who is MHRA? Why we have regulation?
More informationUse of TTC and Human Relevance George E. N. Kass, PhD
Use of TTC and Human Relevance George E. N. Kass, PhD Future Challenges in Developing Assessment Methodologies for Human Health Effects Tokyo, 14 November 2018 Disclaimer The views, thoughts and opinions
More informationChapter Coordinator Guide
Congratulations becoming an ILA Chapter Coordinator! An ILA chapter coordinator plays a vital role in supporting his or her chapter as the group works together to improve literacy for all. ILA s Board
More informationAnnouncement regarding the publication of the results of clinical trials in accordance with Section 42b of the Medicines Act (AMG)
Federal Gazette No 127 dated 24 August 2011, p. 2975-2977 Federal Ministry of Health Announcement regarding the publication of the results of clinical trials in accordance with Section 42b of the Medicines
More informationMedical Cannabis Uses
Medical Cannabis Uses Comprehensive Ordinance Cannabis Policy Subcommittee February 16, 2017 David Guhin, Director Clare Hartman, Deputy Director-Planning Planning and Economic Development 1 City Response
More informationQuality Assurance Policy. for the. Procurement of HIV Point-of-Care Technology. under the UNITAID Grant
Quality Assurance Policy for the Procurement of HIV Point-of-Care Technology under the UNITAID Grant UNICEF Supply Division Quality Assurance Centre and Health Technology Centre Revisions Version Date
More informationCity of Santa Rosa Comprehensive Cannabis Policy
City of Santa Rosa Comprehensive Cannabis Policy Council Policy Subcommittee September 12, 2017 David Guhin, Director Clare Hartman, Deputy Director - Planning Planning and Economic Development 1 Santa
More informationKazuhiko Mori Ministry of Health, Labour and Welfare
Kazuhiko Mori Ministry of Health, Labour and Welfare 1 1. The Establishment of the Japanese Pharmacopoeia 2. Revisions of the Japanese Pharmacopoeia and Changes in Pharmaceutical Regulation 3. Current
More informationPOLICY ON DRUGS & ABUSE
POLICY ON DRUGS & ABUSE 1 Statement of Need Nangia & Co has a strong commitment to the health, safety and welfare of its employees, their families and its customers. Widely available statistics and information
More informationEnvironment, Health and Safety Management System. Management of Contractors Procedure
Environment, Health and Safety Management System Procedure Revision History Revision No. Review Date 1.0 Feb/2018 Description of Change Replacing the Health & Safety Sr. Officer with Health & Safety Specialist/
More informationCalendar of Events. 1 2 June 2006 RAPS 2006 European Conference: EU Regulatory Response to Innovation and Global Competitiveness
Calendar of Events 31 May 2 June 2006 The Validation Manager Venue: Vienna, Austria. 1 2 June 2006 RAPS 2006 European Conference: EU Regulatory Response to Innovation and Global Competitiveness Venue:
More informationTHE GOVERNMENT DECREES: Chapter I GENERAL PROVISIONS
GOVERNMENT S DECREE No. 108/2007/ND-CP OF JUNE 26, 2007, DETAILING THE IMPLEMENTATION OF A NUMBER OF ARTICLES OF THE LAW ON HIV/AIDS PREVENTION AND CONTROL THE GOVERNMENT Pursuant to the December 25, 2001
More informationUpdate from FDA Office of Regulatory Affairs
Update from FDA Office of Regulatory Affairs Ellen F. Morrison Assistant Commissioner for Medical Products and Tobacco Operations Office of Regulatory Affairs U.S. Food and Drug Administration 1 The Impact
More information34th SQA Annual Meeting
34th SQA Annual Meeting Registration Brochure www.sqa.org/sqa2018-1 - The Wonderful World of Quality The Society of Quality Assurance invites you to Anaheim, California for the 34th SQA Annual Meeting
More informationReview Report. (11) Olanzapine Fine Granules 1% "DSEP" (14) Olanzapine OD Tablets 10 mg "DSEP" (17) Olanzapine Tablets 10 mg "Nichi-Iko"
Review Report November 13, 2017 Pharmaceuticals and Medical Devices Agency The following are the results of the review of the following pharmaceutical products submitted for marketing approval conducted
More informationCutanea Life Sciences, Inc. Comprehensive Compliance Program
Cutanea Life Sciences, Inc. Comprehensive Compliance Program Cutanea engages in research, development, manufacture and marketing of dermatology products, including commercialization of those products.
More informationIndividualised Treatment Planning for Radionuclide therapy (Molecular Radiotherapy)
Individualised Treatment Planning for Radionuclide therapy (Molecular Radiotherapy) FMU/ICRP workshop 2017 Glenn Flux Royal Marsden Hospital & Institute of Cancer Research Sutton UK ICRP Task Group 101
More informationControlled Substances Program. For Academic Units
Brigham Young University Page 1 Provo, Utah Controlled Substances Program For Academic Units Last Revised: November 30, 2009 Brigham Young University Page 2 TABLE OF CONTENTS Section Title Page 1.0 Overview
More informationBJA Performance Measures
BJA Performance Measures Timothy J. Willis, Ph.D. Senior Research Associate, CSR, Inc. timothy.willis@ojp.usdoj.gov (202) 514-8045 At the end of this session you will be able to: 1. Explain the value of
More informationThe Role of the Responsible Pharmacist (RP)
The Role of the Responsible Pharmacist (RP) Pharmaceutical industry perspective Vuyo Mokoena: Senior Manager: Monitoring, Compliance and Professional Conduct (MCPC) Overview Background Legislative provision
More informationOrgan Donation from Brain-Dead Donors and the Role of the Japan Organ Transplant Network
Research and Reviews Organ Donation from Brain-Dead Donors and the Role of the Japan Organ Transplant Network JMAJ 54(6): 357 362, 2011 Atsushi AIKAWA* 1 Abstract The Japan Organ Transplant Network (JOT)
More informationGuidance on Drug Master File System in Japan
2 nd China Japan Symposium on Drug Development focusing on IND, Pre Consultation, ti GMP and DMF System March 29, 2011 in Beijing Guidance on Drug Master File System in Japan Takashi YOSHITANI, Ph.D. Master
More informationBIENNIAL REVIEW Compliance with the Drug-Free Schools and Communities Act. St. Johns River State College
BIENNIAL REVIEW Compliance with the Drug-Free Schools and Communities Act St. Johns River State College 2016-2018 The Drug-Free Schools and Communities Act of 1989, Public Law 101-226, requires that St.
More informationBest Practices in FDA 483 and Warning Letter Management and Recovery
Best Practices in FDA 483 and Warning Letter Management and Recovery Elaine C. Messa, RAC Director, Medical Device Quality Systems and Compliance Practice This document is intended to facilitate an oral
More informationCooperation between HALMED and GMP Inspectorate in supervision of manufacturers: Croatia s experience so far
Cooperation between HALMED and GMP Inspectorate in supervision of manufacturers: Croatia s experience so far Ana Boban, MPharm. Agency for Medicinal Product and Medical Devices of Croatia Dubrovnik, 06.05.2013.
More informationUpdate FDA/Center for Food Safety and Applied Nutrition
Update FDA/Center for Food Safety and Applied Nutrition Comments by Susan Mayne, Ph.D. Director Center for Food Safety and Applied Nutrition FDLI Annual Conference May 3, 2018 Food Safety, Nutrition and
More informationComparability and quality of experimental data under different quality systems. S. Caroli Istituto Superiore di Sanità Rome
Comparability and quality of experimental data under different quality systems S. Caroli Istituto Superiore di Sanità Rome Programme of this presentation Part I. Background information Part II. Key aspects
More informationRecommendations for Regulators Cannabis Operations
Recommendations for Regulators Cannabis Operations Developed by: Cannabis Committee American Herbal Products Association 8630 Fenton Street, Suite 918 Silver Spring, MD 20910 www.ahpa.org This document
More informationChanges to the Eighth Edition
Pharmacy Practice and the Law, Eighth Edition Includes Navigate 2 Advantage Access By Richard R. Abood, BS Pharm, JD-Professor Emeritus Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences,
More informationOpen Access MegaJournals
Open Access MegaJournals SPARC Japan Feb 2012 Leading a Transformation in Research Communication Peter Binfield Publisher, PLoS ONE pbinfield@plos.org @p_binfield The Public Library of Science An organization
More informationCommitted to Environment, Health and Safety
Committed to Environment, Health and Safety Environment, Health and Safety Management System and Policy of GCP Applied Technologies Inc. SEPTEMBER 1, 2017 The GCP Environment, Health, and Safety Management
More informationEnsuring protection of public health and patients in member states: priorities, constraints, opportunities
Ensuring protection of public health and patients in member states: priorities, constraints, opportunities Dr. Christa Wirthumer-Hoche AGES Austrian Medicines and Medical Devices Agency Vienna, Austria
More informationStandards of Conduct for Transmission Providers
Standards of Conduct for Transmission Providers Posted and Effective as of December 30, 2016 Puget Sound Energy ( PSE ) is a public utility that owns, operates, and controls facilities used for the transmission
More informationPolicy of Conflict of Interest in Clinical Research
Policy of Conflict of Interest in Clinical Research The Japan Society of Hepatology Academic-industrial collaboration has been assigned as a national strategy to assist in establishing Japan as a nation
More informationNeed for improved post-marketing surveillance in receiving countries and suggestions on how to monitor safety of newly introduced vaccines
Need for improved post-marketing surveillance in receiving countries and suggestions on how to monitor safety of newly introduced vaccines Patrick Zuber - WHO Meeting with vaccine manufacturers 5 April
More informationDivision of Research University Policy
Division of Research University Policy SUBJECT: Effective Date: Policy Number: SATELLITE ANIMAL HOUSING FACILITIES June 24, 2016 Supersedes: August 22, 2014 1 5 Responsible Authorities: Vice President,
More informationEuropean Medicines Enforcement Network
Safeguarding public health European Medicines Enforcement Network 14 th ICDRA, Singapore December 2010 Nimo Ahmed Head of Intelligence Medicines and Healthcare products Regulatory Agency Outline MHRA Enforcement
More informationIncrease Hepatitis B Screening and Vaccinations
17 Increase Hepatitis B Screening and Vaccinations Situation Viral hepatitis is considered to be the most common contagious disease in Japan. Of the estimated three million patients and carriers of viral
More informationCDER Compliance Update
CDER Compliance Update Donald D. Ashley, JD 22 nd Annual GMP by the Sea August 30, 2017 www.fda.gov www.fda.gov 2 Office of Compliance Structure Office of Compliance Office of Drug Security, Integrity
More informationRegulatory Framework for Medical Devices in South Africa. 23 November 2018 Andrea Keyter Deputy Director: Medical Devices
Regulatory Framework for Medical Devices in South Africa 23 November 2018 Andrea Keyter Deputy Director: Medical Devices Medicines and Related Substances Act, 1965 (Act 101 of 1965) Act 72 of 2008 and
More informationPFC Industry Courses and Certifications
PFC Industry Courses and Certifications Americans for Safe Access (ASA) has been a trusted source of cannabis education and training for over 15 years. As a leader in medical cannabis education since 2002,
More informationREGULATIONS IN FOOD INGREDIENTS
REGULATIONS IN FOOD INGREDIENTS Prepared by: CPL Business Consultants The Manor House, Howbery Park, Wallingford, Oxfordshire, OX10 8BA Tel: +44 1491 822 844, info@cplconsult.com, www.cplconsult.com Catherine
More informationRegulatory scientific significance of Japan s ADR relief system
Regulatory scientific significance of Japan s ADR relief system Toshi TOMINGA, Ph.D. Associate Executive Director Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed
More information720 cases. 20 states. Conflict of Interest Declaration. New England Compounding Center (NECC) timeline. (NECC) timeline (continued) 3/28/2013
Conflict of Interest Declaration Compounding at a Crossroads: The Federal and State Outlook Christopher J. Topoleski has no actual or potential conflicts of interest in relation to this activity Christopher
More informationQuality, Safety and Sourcing in Unlicensed Medicines
Quality, Safety and Sourcing in Unlicensed Medicines with Andrew Trouton Managing Director, UL Medicines Agenda Welcome What is an unlicensed medicine? When should you consider using an unlicensed medicine?
More informationGood Laboratory Practice. EU-Serbia screening meeting Brussels, 19 June 2014
Good Laboratory Practice EU-Serbia screening meeting Brussels, 19 June 2014 Table of contents 1. Background information on the principles of GLP 2. EU legal basis for GLP 3. Role of Member States 4. Role
More informationMerced, California Next Steps and Strategies for Successful Implementation of Cannabis-Related Health and Safety Regulations
Merced, California Next Steps and Strategies for Successful Implementation of Cannabis-Related Health and Safety Regulations Presented by: Neil Hall Arcelia Herrera May 9, 2017 4745 Mangels Blvd, Fairfield,
More informationPOLICIES & PROCEDURES
Policy Name: Page 1 of 7 I. POLICY Evidence-based clinical research regarding influenza has shown that the best method for prevention and control of seasonal influenza is vaccination. The purpose of this
More informationNIGERIAN EXPERIENCE OF THE BIOLOGICAL AND TOXIN WEAPONS CONVENTION
MEETING OF THE STATES PARTIES TO THE CONVENTION ON THE PROHIBITION OF THE DEVELOPMENT, PRODUCTION AND STOCKPILING OF BACTERIOLOGICAL (BIOLOGICAL) AND TOXIN WEAPONS AND ON THEIR DESTRUCTION BWC/MSP/2007/WP.8
More informationRite aid employment verification
Rite aid employment verification Information, reviews and commentary for Rite Aid Offices located at 30 Hunter Lane, Camp Hill, PA, 17011. support team, advancement opportunities at every level and training
More information